SCHEMBL20396124

SCHEMBL20396124

O=C(O)N1CCC2(CCC(O)CO2)CC1

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.33
FFAR4 Q5NUL3 6/20 0.32
CNR2 P34972 1/20 0.31
MGLL Q99685 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3352527 0.84 CNR2 (0.35) FFAR4CNR2MGLL
SCHEMBL3352521 0.84 CNR2 (0.35) FFAR4CNR2MGLL
SCHEMBL20395931 0.84 CNR2 (0.35) FFAR4CNR2MGLL
SCHEMBL21625018 0.81 LMNA (0.32) FFAR4
SCHEMBL16416530 0.78 CNR2 (0.41) CNR2MGLL
SCHEMBL368761 0.77 USP2 (0.45) MGLL
SCHEMBL13827693 0.77
SCHEMBL15188955 0.77 KMT2A (0.35)
SCHEMBL20396096 0.76 MGLL (0.34) FFAR4MGLL
SCHEMBL18341792 0.75 VNN1 (0.37) MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10626125-B2 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors PFIZER INC. (US) 2020-04-21 US disclosed
US-20190276472-A1 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS PFIZER INC. (US) 2019-09-12 US disclosed
US-10329308-B2 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors PFIZER INC. (US) 2019-06-25 US disclosed
US-20180208607-A1 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS PFIZER INC. (US) 2018-07-26 US disclosed
WO-2018134695-A1 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS PFIZER INC. (US) 2018-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276472-A1 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS MAG, PYM1, HIF1AN HSD11B1 788/4885FFAR4 983/4885CNR2 477/4885
US-10626125-B2 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors MAG, PYM1, HIF1AN HSD11B1 788/4885FFAR4 983/4885CNR2 477/4885
US-20180208607-A1 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS MAG, PYM1, HIF1AN HSD11B1 788/4885FFAR4 983/4885CNR2 477/4885
US-10329308-B2 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors MAG, PYM1, HIF1AN HSD11B1 788/4885FFAR4 983/4885CNR2 477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.